PIK3CB and neoplasm: Although further investigation on the direct effect of PI3K/mTORi on T cells and macrophages is warranted, these data suggest that these inhibitors do not hinder immune responses by directly interfering with the functionality of T cells or macrophages in the tumours and might be suitable candidates for combination therapy with PD‐1 blockade.